USPTO Patent Application for Metabolic Syndrome Treatment
Summary
The USPTO has published a patent application (US20260083753A1) for compositions and methods to treat metabolic syndrome. The application, filed by Kotha Sekharam, details improved compositions with enhanced solubility and bioavailability.
What changed
This document is a USPTO patent application (US20260083753A1) for novel compositions and manufacturing methods for treating metabolic syndrome and other metabolic disorders. The application, filed on July 21, 2025, and published on March 26, 2026, describes an extrudate with improved solubility, bioavailability, and therapeutic effect at a low dose, potentially impacting pharmaceutical development in this area.
As this is a patent application, it does not impose direct compliance obligations on regulated entities. However, it represents a new development in intellectual property within the pharmaceutical sector. Companies involved in metabolic disorder treatments should be aware of this filing for competitive intelligence and potential licensing or infringement considerations.
Archived snapshot
Mar 26, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Compositions for the Treatment of Metabolic Syndrome and Other Metabolic Disorders, and Methods of Manufacture
Application US20260083753A1 Kind: A1 Mar 26, 2026
Inventors
Kotha SEKHARAM
Abstract
The subject invention provides improved compositions for metabolic syndrome and methods of preparing the compositions via, for example, hot-melt extrusion. The resulting extrudate has improved solubility, bioavailability and therapeutic effect for treatment of metabolic syndrome at a low dose.
CPC Classifications
A61K 31/56 A61K 47/10 A61K 47/18 A61K 47/22 A61K 47/32 A61P 3/00
Filing Date
2025-07-21
Application No.
19274778
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Pharma (A61K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Pharma (A61K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.